title: Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.
abstract: BACKGROUND
  Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization.
  
  
  OBJECTIVE
  Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC.
  
  
  METHODS
  Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011-2013) of the National Health Insurance Fund.
  
  
  RESULTS
  A total of 55,039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55-0.56). The prevalence of CD 0.20% (95% CI, 0.19-0.20), and UC was 0.34% (95% CI, 0.33-0.34). The prevalence both in men and women was the highest in the 20-39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44% and 15%) followed by adult CD (33% and 9%), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group.
  
  
  CONCLUSIONS
  The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Kurti
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Vegh
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Petra A
authors.initials: PA
authors.lastname: Golovics
authors.affiliation: Strategic Analysis Department, National Health Insurance Fund (OEP), Budapest, Hungary.
authors.forename: Petra
authors.initials: P
authors.lastname: Fadgyas-Freyler
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Krisztina B
authors.initials: KB
authors.lastname: Gecse
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Lorant
authors.initials: L
authors.lastname: Gonczi
authors.affiliation: Strategic Analysis Department, National Health Insurance Fund (OEP), Budapest, Hungary.
authors.forename: Judit
authors.initials: J
authors.lastname: Gimesi-Orszagh
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Barbara D
authors.initials: BD
authors.lastname: Lovasz
authors.affiliation: 1st Department of Medicine, Semmelweis University, Budapest, Hungary. Electronic address: lakatos.peter_laszlo@med.semmelweis-univ.hu.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Lakatos
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001688:Biological Products / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D015212:Inflammatory Bowel Diseases / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D010045:Outpatients; D017678:Sex Distribution; D055815:Young Adult
chemical_list: D001688:Biological Products; D007166:Immunosuppressive Agents
keywords: Drug treatment strategy; Epidemiology; Inflammatory bowel disease; Prevalence; Public health registry data